Imdusiran (AB-729)
Chronic Hepatitis B Virus (HBV)
Phase 2Active
Key Facts
About Arbutus Biopharma
Arbutus Biopharma is a virology-focused biotech leveraging a combination drug development strategy to pursue a functional cure for chronic hepatitis B. Its innovative pipeline, anchored by the RNAi therapeutic imdusiran, employs a 'Suppress, Reduce, Boost' methodology to attack the virus through complementary mechanisms of action. The company is led by an experienced team with a strong track record in drug development, biotech creation, and strategic finance, positioning it to advance its clinical-stage assets toward the market.
View full company profileTherapeutic Areas
Other Chronic Hepatitis B Virus (HBV) Drugs
| Drug | Company | Phase |
|---|---|---|
| AB-101 | Arbutus Biopharma | Phase 1/2 |
| AB-161 | Arbutus Biopharma | Phase 1 |